Healthcare & Pharmaceuticals

Market-leading effective advice built on strong foundations

Healthcare and life sciences companies come to King & Wood Mallesons not just because we have the right expertise and the best people, but because we put in the work it takes to understand the sector.

Navigating healthcare legislation is rarely straightforward given scientific advances, ever-changing government regulation and strict ethical considerations.

We make sure our legal advice is based on a comprehensive knowledge of current developments in the industry. We scour legal and commercial developments in pharmaceuticals and medicine as they happen and share them with clients so that we can all stay at the cutting edge.

Navigating the pandemic and rapidly changing settings

We have helped clients navigate the challenges presented by the COVID-19 pandemic. We understand better than most this heavily regulated environment, the drivers of rapid changes across the health sector, opportunities for novel technologies and treatments, and evolving healthcare models.

Our large portfolio of health sector clients equips us with insights into issues most likely to impact you. We know how to best manage and resolve commercial and legal issues, no matter the complexity.

KWM’s health sector specialists bring first-hand experience assisting on a full range of transactions and matters, including:

  • Complex Patent Disputes
  • Major M&A Transactions
  • Product Liability Defences
  • High-Stake Regulatory Investigations
  • Provision of Ongoing Targeted Commercial & Regulatory Advice.

We know you must move fast sometimes to get a deal done, or to respond to an issue, so we focus on making sure you get a straight answer quickly.

Our lawyers advise companies working in:

  • Pharmaceuticals – including originators and generics
  • Biotechnology
  • Research & Eevelopment
  • Medical Devices
  • Health Insurance
  • Health Services
  • Hospitals & medical Facilities
  • Aged Care & Retirement Villages.

We also advise private equity firms, investors and financial advisers to the sector.

JP | EN
Current site :    JP   |   EN
Australia
China
China Hong Kong SAR
Japan
Singapore
United States
Global